Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE: 002390)
Health Care · Pharmaceuticals · CN
CN¥3.04
-4.10% today · -19.4% 1Y
Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE: 002390) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $857.59M and employs 4,702 people.
Over the last twelve months the share price has lost 19.4%, trading between 2.54 and 4.15.
Tweenvest scores Guizhou Xinbang Pharmaceutical Co., Ltd. across four factors: quality 79/100, value 71/100, growth 45/100, dividend 58/100. Its strongest factor is quality.
002390 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $857.59M
- Revenue (TTM)
- $788.95M
- P/E
- 45.12
- EPS
- 0.07
- Dividend yield
- 2.96%
- Beta (5Y)
- 0.12
- 52-week high
- CN¥4.15
- 52-week low
- CN¥2.54
- Avg volume (3M)
- —
- Shares outstanding
- 1.90B
- Employees
- 4,702
- Next earnings
- —
About Guizhou Xinbang Pharmaceutical Co., Ltd.
Guizhou Xinbang Pharmaceutical Co., Ltd. specializes in the entire process of researching, developing, manufacturing, and distributing both traditional Chinese herbal medicines and cutting-edge biological pharmaceuticals. The company's operations span across China and international markets. Its diverse range of pharmaceutical offerings covers treatments for cardiovascular and cerebrovascular conditions, digestive system disorders, endocrine imbalances, tumor and immune regulation, blood system ailments, rheumatism and rheumatoid diseases, and urinary tract issues. Additionally, it provides antipyretic analgesics, cold medications, gynecological therapies, and anti-infective drugs. Founded in 1995, the firm's headquarters are situated in Guiyang, China.
- ISIN
- CNE100000NG5
- Founded
- 1995
- Listed since
- Apr 16, 2010
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,247.37 | -0.64% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.00 | +1.02% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.91 | -1.08% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.03 | -0.14% |
Figures last refreshed Aug 18, 2026.